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Resumo
A pele, enquanto maior órgão do corpo humano, pode possuir 
um papel fundamental no diagnóstico precoce de doenças sis-
témicas. As manifestações cutâneas podem ser a primeira ma-
nifestação de doenças hematológicas oncológicas (linfoma de 
Hodgkin, leucemia linfocítica crónica, leucemia mielóide agu-
da),	podendo	estas	ser	classificadas	em	específicas,	quando	
são	causadas	pela	 infiltração	de	células	malignas	na	pele	ou	
pela expansão loco-regional da doença tumoral; ou inespecí-
ficas,	pela	desregulação	imune	que	ocorre	nos	doentes	onco-
lógicos, (caracterizadas pela ausência de células tumorais). As 
lesões	 inespecíficas	são	mais	 frequentes,	 têm	características	
polimórficas	 e	 podem	 preceder,	 ser	 concomitantes	 ou	 ocor-
rer	após	o	diagnóstico	da	neoplasia	oculta.	Neste	artigo	serão	
descritas algumas das doenças cutâneas mais frequentemente 
associadas a neoplasias hematológicas; nomeadamente, der-
matoses neutrofílicas (síndrome de Sweet, pioderma gangre-
noso e policondrite recidivante), doenças do tecido conjuntivo 
(dermatomiosite), prurido de etiologia desconhecida e doenças 
vesico-bolhosas	(pênfigo	paraneoplásico	e	vulgar).	Serão	ain-
da abordadas outras menos frequentes mas cuja associação 
a neoplasias está bem descrita: amiloidose, eritemas reactivos, 
dermatoses vasculares (livedo reticularis, eritromelalgia e vas-
culites) e outras (acanthosis nigricans, sinal de Leser-Trélat e 
ictiose adquirida). O principal objectivo desta revisão é o de sa-
lientar o importante papel de certas dermatoses que podem ser 
a manifestação inicial de doenças hematológicas oncológicas, 
levando a um diagnóstico diferencial mais direccionado.
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logy and etiology, being their link to the internal malignancy 
incompletely understood. Some theories support the role of 
cytokine production from the tumor and its accessory cells, 
whilst others relay on the production of autoantibodies by the 
cancer cells as a cause of the paraneoplastic syndromes.2 
Clinically, these manifestations can precede, follow or have a 
parallel course with the underlying malignancy. Even though 
they	are	not	specific	of	cancer,	they	alert	the	doctor	to	con-
duct a detailed investigation towards excluding a neoplastic 
etiology. In this review we will focus on the most frequent pa-
Introduction
Paraneoplastic dermatoses are a group of skin disorders that 
are associated to an underlying neoplasm, regardless of their 
distance from it.1 They exhibit a variable morphology, patho-
Abstract
The skin, as the largest organ of the human body, can have 
a key role in the early diagnosis of systemic diseases. Cuta-
neous manifestations can be the initial symptom of certain 
malignant hematological diseases (Hodgkin lymphoma, 
chronic lymphocytic leukemia, acute myeloid leukemia). 
These can be classified as specific when caused by direct 
invasion of malignant cells in the skin or by loco-regional ex-
pansion of the tumoral disease or unspecific when caused 
by the altered regulation of the immune system typical of 
oncologic patients (characterized by absence of neoplastic 
cells in the skin). The unspecific injuries are more frequent, 
have polymorphous appearance and may precede, follow 
or have a parallel course with the underlying malignancy. In 
this article, the most frequent cutaneous diseases associa-
ted with hematological malignancies are reviewed, namely 
neutrophilic dermatoses (Sweet syndrome and pyoderma 
gangrenosum), connective tissue diseases (dermatomyo-
sitis), pruritus of unknown origin and vesiculobullous disor-
ders (pemphigus vulgaris and paraneoplastic pemphigus). 
Although less common, other diseases are also associated 
with malignancy such as amyloidosis, reactive erythemas, 
vascular dermatoses (livedo reticularis, erythromelalgia and 
vasculitis) and other disorders (acanthosis nigricans, sign of 
Leser-Trélat and acquired ichthyosis). The main purpose of 
this review is to highlight the relevance of cutaneous mani-
festations that can be the first symptom of hematological ma-
lignancies and lead to differential diagnosis.
Keywords: Hematologic Neoplasms; Paraneoplastic Syndro-
mes; Skin Diseases.
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raneoplastic cutaneous manifestations as well as their patho-
physiology, differential diagnosis and prognostic relevance.
Table 1 summarizes the different cutaneous manifestations 
of hematologic diseases.
Neutrophilic Dermatoses
This is a group of disorders that includes Sweet syndrome 
and pyoderma gangrenosum and is characterized by an in-
tense	dermal	inflammatory	infiltrate	composed	of	neutrophils	
with little evidence of vasculitis.3
Sweet syndrome (SS) was initially described in 1964 by Dr. 
Robert Sweet as an acute febrile dermatosis, being characte-
rized by the presence of fever, leukocytosis with neutrophilia 
and painful erythematous papules, nodules and plaques in-
volving the limb extremities and face (Fig. 1). Histologically, 
they	 show	 a	 characteristic	 diffuse	 neutrophilic	 infiltrate	 in	
the upper dermis.4	SS	can	be	classified	upon	its	clinical	set-
ting into: classical or idiopathic, malignancy-associated and 
drug-induced.4
Classical SS typically occurs in women aged between 30 
and 50 years old and it is frequently preceded by an upper 
respiratory	 tract	 infection,	 inflammatory	 bowel	 disease	 or	
pregnancy.5 Malignancy-associated SS can occur as a pa-
raneoplastic	syndrome	and	it	may	be	the	first	symptom	of	an	
underlying	 malignancy.	 Approximately	 20%	 of	 the	 patients	
with SS have an associated cancer (being acute myeloge-
nous	leukemia	the	most	common	one)	and	in	40%	of	these,	
the tumor is diagnosed one month after the appearance of the 
skin lesions.2 It occurs more frequently in men and its recur-
rence is usually associated with the diagnosis or recurrence 
of the malignancy. Drug-induced SS most commonly occurs 
in patients taking granulocyte-colony stimulating factors, an-
tibiotics, anti-epileptics, diuretics and oral contraceptives, 
among others.
Pyoderma gangrenosum (PG) occurs as tender erythe-
matous or violaceous nodules with tendency to ulcerate and 
involve large body areas occurring in the lower extremities, 
buttocks, abdomen and face (Fig. 2). It shows endothelial 
swelling	and	fibrinoid	necrosis	with	a	predominance	of	leuko-
cytes and heals leaving atrophic scars. It is estimated that 
50%	of	cases	of	PG	are	associated	with	a	systemic	disorder	
(Crohn’s disease, ulcerative colitis), being associated with 
malignancy	in	7%	of	the	cases	(acute	myelogenous	leukemia	
and multiple myeloma are the most common ones).2,3
The differential diagnosis of neutrophilic dermatoses inclu-
des cellulitis, lymphangitis, panniculitis, syphilis, tuberculo-
sis, leukemia cutis, urticaria, Behçet’s disease, lupus erythe-
matosus, dermatomyositis and erythema nodosum.5
Systemic corticosteroids are the therapeutic gold standard; 
in those patients with absolute contraindication to these dru-
gs or active infections, potassium iodide or colchicine can be 
used instead (in SS). The lesions may solve spontaneously 
or	undergo	a	 relapsing	and	 remitting	course	 (up	 to	33%	of	
recurrences in classical SS),5 being the prognosis usually the 
same as the underlying disease.
Relapsing	polychondritis	(RP)	is	an	inflammatory	condition	
affecting cartilaginous tissue, mainly in the ear, nose and 
tracheobronchial cartilage. It occurs in all age groups and 
affects men and women equally. One of the most common 
presenting features is acute painful swelling and redness of 
the	external	ear,	which	occurs	in	up	to	40%	of	patients.6
The currently accepted diagnostic criteria were described 
by McAdamet et al7 and are1: recurrent chondritis of both au-
ricles2;	 inflammatory	 arthritis3; chondritis of nasal cartilage4; 
ocular	inflammation	and	chondritis	of	upper	respiratory	tract,	
cochlear	 and/	 or	 vestibular.	 In	 order	 to	diagnose	RP,	 three	
or more of the above need to be present, or one plus his-
tological diagnosis, or chondritis in two separate locations 
with good response to corticosteroids.7	Over	30%	of	patients	
have an associated disorder, usually autoimmune or hema-
tologic.6 The autoimmune disorders associated are systemic 
vasculitis, systemic lupus erythematosus, Sjögren syndrome, 
overlap connective tissue disorders, rheumatoid arthritis, 
spondyloarthropathies and psoriasis.6 Regarding the hema-
tologic diseases, they include myelodysplastic syndromes 
and Hodgkin’s disease.6,7 The occurrence of RP together with 
myelodysplasia is a marker of poor prognosis.7
The	treatment	 is	based	on	non-steroidal	anti-inflammatory	
drugs in patients with mild disease and systemic corticoste-
roids in those with pulmonary or renal involvement.6
Connective Tissue Diseases
In this section we will focus on dermatomyosistis, the con-
nective tissue disorder with cutaneous manifestations most 
Table 1: Cutaneous paraneoplastic manifestations of hema-
tological malignancies.
Group of disorder Paraneoplastic cutaneous manifestation
Inflammatory
Neutrophilic	dermatoses:	Sweet	syndrome,	
Pyoderma gangrenosum
Relapsing polychondritis
Dermatomyositis
Erythroderma
Erythema gyratum repens
Vesiculobullous Pemphigus vulgarisParaneoplastic pemphigus
Vascular
Vasculitis
Amyloidosis
Erythromelalgia
Others
Pruritus of unknow origin
Acquired Icthyosis
Sign of Leser-Trélat
Acanthosis nigricans 
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frequently associated with hematological malignancies. The 
connective tissue diseases are a group of idiopathic in-
flammatory	myopathies	with	an	autoimmune	etiology	charac-
terized by progressive and symmetrical weakness of proximal 
muscles	 and	 specific	 cutaneous	 lesions.	 Dermatomyositis	
(DM)	belongs	to	a	group	of	 idiopathic	 inflammatory	myopa-
thies with an autoimmune etiology characterized by speci-
fic	 cutaneous	 lesions.8	 Its	 first	 association	with	malignancy	
was described in 1916, in a patient with DM and stomach 
adenocarcinoma.8 Several postulates have been proposed 
regarding the mechanisms of association between DM and 
malignancy; namely the mimicry with endothelial antigens, 
cross-reactions between skin and muscle antigens and chro-
nic immune stimulation (typical of DM), that would cause the 
activation of B and T cells with consequent malignant trans-
formation of lymphocytes.9
The diagnosis of DM is based on Bohan and Peter’s crite-
ria: symmetrical muscle weakness progressing over weeks 
to	months;	 typical	 histological	 findings	 on	muscle;	 elevation	
in serum muscle enzymes (creatine kinase, aldolase, lactate 
dehydrogenase); myopathic changes in electromyography 
and characteristic cutaneous features.9 Concerning the clinical 
features, they are an heliotrope rash (blue-purple discoloration 
of the upper eyelids) associated with local edema, “V sign” 
(an erythematous rash on the face, neck and anterior chest) or 
back and shoulders (shawl sign) and Gottron’s papules (raised 
violaceous rash in the knuckles).10 Dysphagia and respiratory 
muscle involvement are more frequent in the cancer group, 
being	respiratory	insufficiency	a	frequent	cause	of	death.8
The most frequent types of hematological malignancies rela-
ted	to	DM	are	B-cell	lymphoma	(65%	of	cases),	T-cell	lympho-
ma	(12.5%),	Hodgkin’s	disease,	multiple	myeloma,	myelodys-
plastic syndromes, hairy cell leukemia and acute lymphocytic 
leukemia.9	In	approximately	50%	of	the	patients,	DM	is	diagno-
sed before the hematological malignancy, with a mean interval 
onset of less than two years. Compared to patients with non-
-malignancy associated DM, these ones are older (mean age 
of	57	years	old)	and	frequently	of	the	female	gender.	Also,	they	
less frequently exhibit joint involvement and anti-Jo1 antibody.9
The differential diagnosis of dermatomyositis includes sys-
temic lupus erythematosus, systemic sclerosis, psoriasis, 
airborne or contact dermatitis, atopic dermatitis, photodrug 
eruption and cutaneous T-cell lymphoma.11
Regarding	 the	 treatment,	 prednisone	 is	 the	 first	 option,	
followed by corticosteroid-sparing drugs (azathioprine, cy-
closporine). The clinical course is dependent on the under-
lying malignancy, as it is proven by the improvement on DM 
clinical features after initiation of anti-tumoral treatment. Due 
to its close association to malignancies, particularly hemato-
logic ones, when DM is diagnosed, a systemic tumor investi-
gation should be performed.
Pruritus of Unknown Origin
Pruritus is the most common symptom in dermatology and it 
can	occur	in	very	distinct	clinical	settings.	It	is	defined	as	an	
unpleasant sensation provoking the desire to scratch.12 It resul-
ts from the activation of the sensory nervous system involving 
the peripheral nervous system, dorsal root ganglia, spinal cord 
and brainstem. It can be proprioceptive (if its origin is in the 
skin	due	to	inflammation	or	dryness),	neuropathic	(pathologi-
cally located along the afferent pathway), neurogenic (origina-
tes centrally but without evidence of neurologic pathology) or 
psychogenic. It can be further divided into chronic (lasting for 
more than six weeks), intractable, localized or generalized.
Paraneoplastic itch occurs before or during the diagnosis 
of the malignancy, it is not caused by tumoral invasion or ex-
trinsic compression and its course is dependent on cancer 
therapy.13 It is associated with hematological disorders, na-
mely	Hodgkin’s	disease	(up	to	30%	of	cases),13 multiple mye-
loma, lymphoma and leukemia.
When associated to Hodgkin’s disease (HD), it may prece-
de	the	diagnosis	of	the	disease	up	to	five	years	and	it	is	typi-
cally worse at night, starting in the legs and then spreading 
proximally. When generalized, it is more common in nodular 
sclerosis type of HD and, when localized, it usually occurs in 
the areas drained by lymphatic vessels invaded by the tumor. 
Grover’s disease is an extremely pruritic papulovesicular di-
sease that occurs in the trunk of adult men, being associated 
Figure 1: Painful erythematous papules involving the back of a 
patient with Sweet syndrome.
Figure 2: Tender erythematous nodules with central ulceration, 
characteristic of pyoderma gangrenosum.
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with hematological malignancies (even though it is not clear 
whether its association with malignancy is caused by the 
cutaneous effect of fever and night sweats typical seen with 
these conditions).13 It has been considered a B symptom in 
the 60’s, due to its non-negligible contribution to the patient’s 
quality of life; however, a few years later it was replaced by 
weight loss.14 Also worth mentioning is pruritus as a feature of 
dermatomyositis	(up	to	38%	of	cases),12 which is itself asso-
ciated to malignancy.
The secondary skin changes of pruritus include excoria-
tions,	 lichenification,	 post-inflammatory	 hyperpigmentation,	
shiny	finger	nails,	prurigo	nodules	and	“butterfly	sign”	(areas	
that the patients are not able to scratch in the upper back and 
present a different coloration from the remaining skin) (Fig. 
3).12 The diagnosis can be performed by noticing these chan-
ges and asking the patient about its evolution during the day 
(malignancy associated pruritus usually occurs at night and 
impairs sleep while psychogenic one does not).
The differential diagnosis involves all the conditions that 
may potentially cause pruritus as a major symptom; namely 
infestations	 (scabies,	 pediculosis),	 inflammatory	 disorders	
(atopic or contact dermatitis, psoriasis, lichen planus, urtica-
ria, drug eruptions, mastocytosis), autoimmune connective 
tissue disorders (lichen sclerosus, dermatomyositis, systemic 
and cutaneous lupus erythematosus), infections (viral, bacte-
rial, fungal or parasitic) and neoplastic disorders (cutaneous 
malignancies).11
The	 treatment	 is,	 in	 general,	 insufficient	 and	 includes	
emollients, topical steroids, antihistamines, phototherapy and 
oral	antihistamines.	Definite	resolution	can	only	be	achieved	
after treating the underlying disease.
Vesiculobullous Disorders
This group of disorders shows typical microscopic features 
namely epidermal cell separation, intraepidermal blister for-
mation and deposition of immunoreactants in intercellular 
spaces of epithelial tissue.15 Its physiopathology is based 
on	the	production	of	autoantibodies	that	target	specific	pro-
teins (desmogleins), responsible for the binding to the cell 
surface of keratinocytes of skin and mucous membranes. 
Pemphigus can be divided into two major subtypes: pem-
phigus vulgaris (the most common form), and paraneoplastic 
pemphigus.15 Microscopically, pemphigus vulgaris shows a 
pauci-inflammatory	infiltrate	with	prominent	acantholysis	whe-
reas paraneoplastic pemphigus has a marked mononuclear, 
lichenoid	inflammatory	infiltrate	at	the	dermo-epidermal	junc-
tion. Acantholysis is also present but in a lesser extent than in 
pemphigus vulgaris.15
In pemphigus vulgaris (PV) patients exhibit circulating IgG 
autoantibodies that target Desmoglein 3, located on the lower 
portion of epidermis, affecting primarily the mucous membra-
nes throughout the body. Patients present with painful ero-
sions of the mouth and mucous membranes of the pharynx, 
larynx, esophagus, eyes, nose and genitalia.16
Paraneoplastic	 pemphigus	 (PNP)	 has	 some	 features	 that	
allow us to distinguish it from PV, such as persistent and pain-
ful stomatitis, involvement of other mucosae and, in some ca-
ses, the presence of polymorphous, vesicular lichenoid skin 
eruptions	(Fig.	4).	Also,	in	PNP	the	lesions	typically	involve	the	
palms and soles whereas in PV this rarely occurs.17
Anhalt et al	 proposed	 five	 classification	 criteria	 to	 define	
paraneoplastic pemphigus18:
1. Painful mucosal erosions and a polymorphous skin erup-
tion with papular lesions progressing to blisters and ero-
sive lesions affecting the trunk, extremities, palms and 
soles;	in	the	context	of	an	occult	or	confirmed	neoplasia;
2. Cutaneous histologic changes such as intraepidermal 
acantholysis, keratinocyte necrosis and vacuolar-interfa-
ce dermatitis;
3. Deposition of IgG and complement in the epidermal in-
tercellular spaces, as well as granular-linear complement 
deposition along the epidermal basement membrane, on 
direct	immunofluorescence	testing;
4. Serum autoantibodies that bind the cell surface of skin and 
mucosae in a pattern typical of pemphigus but in addition 
bind to simple, columnar and transitional epithelia;
5. Presence of a complex of four proteins immunoprecipitated 
from keratinocytes by the circulating autoantibodies.
Figure 3: Post-inflammatory hyperpigmentation and prurigo 
nodules in a patient with severe pruritus.
Figure 4: Paraneoplastic pemphigoid showing polymorphous, 
vesicular lichenoid skin eruptions.
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The most frequent malignancies in these patients are Kapo-
si sarcoma, Hodgkin and non-Hodgkin lymphoma, chronic 
lymphocytic leukemia, Waldenstrom macroglobulinemia and 
thymomas,15,17,19 being lymphoproliferative disease the most 
common one.15 The onset of pemphigus precedes the diag-
nosis of a malignancy in more than half of the cases.2
The differential diagnosis includes bullous pemphigoid, 
Hailey-Hailey disease (if there is localized oral disease), li-
chen planus, impetigo, subacute cutaneous lupus erythema-
tosus and aphthous dermatitis.11
Regarding the treatment, most patients with PV have a good 
response to moderate- or high-dose systemic corticosteroid 
therapy.15 Other therapies that can be used are intravenous 
immunoglobulin, plasmapheresis, corticosteroid-sparing dru-
gs and rituximab.17 In paraneoplastic pemphigus, there is 
usually	no	response	to	any	of	these	therapies,	carrying	a	90%	
mortality rate within a few months after diagnosis, indepen-
dent of the course of the malignancy. In few reports, success-
ful treatment of the associated neoplasia was associated with 
resolution	on	PNP.17
Amyloidosis
Amyloidosis	 is	defined	as	 in	 vivodeposition	of	material	with	
specific	characteristics:	fibrillar	appearance	on	electron	mi-
croscopy; amorphous eosinophilic appearance on hemato-
xylin and eosin staining; beta-pleated sheet structure as ob-
served	by	X-ray	diffraction	pattern;	apple-green	birefringence	
on Congo red staining, solubility in water and buffers of low 
ionic strength.20	All	types	of	amyloid	consist	of	one	major	fi-
brillar	protein	that	defines	the	type	of	amyloid.	Many	mecha-
nisms of protein function contribute to amyloidogenesis inclu-
ding defective or absent physiologic proteolysis, mutations 
involving changes in thermodynamic or kinetic properties and 
pathways	that	are	yet	to	be	defined.20
Primary amyloidosis is a type of amyloidosis in which no 
predisposing cause is found. It has a different distribution 
from its typical form, involving the skin and occurring in as-
sociation with hematological malignancies. In contrast, se-
condary amyloidosis usually involves parenchymal structures 
and	is	associated	with	chronic	inflammatory	disorders.2
In terms of diagnosis, newer methods have been deve-
loped including subcutaneous fat biopsy. This is because 
recent studies have recognized the role of capillaries in the 
subcutaneous fat which are often involved in patients with 
systemic amyloidosis and can provide enough tissue for the 
diagnosis of amyloid, immunostaining, and, in some cases, 
amino acid sequence analysis.
Primary amyloidosis is due to a plasma cell dyscrasia that 
does	 not	 fulfill	 the	 criteria	 for	 multiple	 myeloma,	 being	 the	
precursor proteins immunoglobulin light chains rather than 
heavy chains. It has been associated with multiple myeloma 
(13-26%)	and	monoclonal	gammopathy	(90%).2 Patients with 
a	multiple	myeloma	have	a	16%	probability	of	having	amyloi-
dosis due to deposition of light-chain elements.
Clinically,	amyloidosis	presents	as	firm	skin-colored	waxy	
papules	or	plaques	occurring	typically	in	the	face;	infiltration	
of the tongue can lead to macroglossia and skin trauma may 
cause the formation of purpura.11 Other manifestations are 
nephrotic syndrome, heart failure, splenomegaly, liver injury 
and hepatomegaly, peripheral neuropathy and mucocuta-
neous lesions.
The differential diagnosis of amyloidosis includes facial pa-
pules, mucinoses and multiple adnexal tumors.
The treatment is usually directed towards the main organ 
involved	 and	 the	 underlying	 etiology	 (chronic	 inflammatory	
disorder, malignancy), being the response very variable. The 
prognosis for myeloma-related amyloidosis is poor, with a 
survival of less than one year.2
Reactive Erythemas and Erythroderma
These are a group of cutaneous disorders characterized 
by migratory annular, arciform or polycyclic erythematous 
lesions, being erythema gyratum repens (EGR) the only en-
tity considered to be a paraneoplastic disease. Similarly to 
erythroderma, they can occur in association with solid malig-
nancies (namely EGR), such as lung, esophageal and breast 
cancer.21
Erythema gyratum repens (EGR), can be distinguished by 
rapidly evolving scaly, erythematous bands that form con-
centric rings resulting in a “wood-grain” appearance (Fig. 5). 
They usually cover the trunk and proximal extremities and can 
be extremely pruritic. Their association with malignancy is 
well established, but there is not a predominance of any par-
ticular type of cancer (some of the reported cases were with 
lung cancer, Hodgkin lymphoma and multiple myeloma).21
Erythroderma and exfoliative dermatitis typically present 
with generalized redness and scaling involving more than 
90%	 of	 the	 body	 surface	 area.	 Lymphomas	 (Hodgkin	 and	
non-Hodgkin), leukemias and myelodysplastic syndromes 
are the most common malignancies linked to these disorders 
even though erythroderma is thought to be caused by the 
Figure 5: Erythema gyratum repens with the typical scaly, ery-
thematous bands that form concentric rings resulting in a “wood- 
-grain” appearance.
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direct tumor invasion and not by a paraneoplastic process.2
The differential diagnosis of reactive erythemas includes 
drug eruptions, psoriasis vulgaris, pityriasis rubra pilaris, in-
fections (HIV, Staphylococcus aureus), erythema chronicum 
migrans (usually accompanied by a history of a tick bite), 
annular urticaria, granuloma annulare, sarcoidosis, leprosy, 
secondary syphilis, tinea corporis, cutaneous T-cell lympho-
ma and subacute lupus erythematosus.21
The	 treatment	 is	based	on	 the	 identification	of	 the	under-
lying condition as the course of the cutaneous lesions follows 
the one of the underlying process. Systemic and topical corti-
costeroids provide symptom relief.
Vascular Dermatoses
The common feature of all the conditions is that they may oc-
cur as reactive processes in association with other diseases. 
The histopathologic characteristics of the lesions range from 
mild,	 perivascular	 dermal	 infiltration	with	 inflammatory	 cells	
and vasodilation to various degrees of vessel damage (endo-
thelial	swelling	to	fibrinoid	necrosis).22
Livedo reticularis is	a	common	skin	finding	that	consists	of	
a	mottled	reticular	blue-violet	pattern	reflecting	an	increase	in	
deoxygenated blood within the venous plexus of the skin due 
to capillary obstruction by small clots. It can be due to arterio-
lar	vasospasm	or	sluggish	flow	due	to	hypercoagulability	or	
luminal pathology.11 It usually occurs on the lower limbs but, 
in the setting of systemic diseases, it may be widespread. It 
can be associated with several diseases, namely connective 
tissue diseases, Raynaud’s phenomenon, vasculitis, calci-
phylaxis, livedoid vasculopathy, hypercoagulability, polycy-
themia vera, thrombocythemia, infections, drugs or neoplas-
ms (pheochromocytoma, multiple myeloma). It may improve 
with warming of the legs but in some cases, the discoloration 
may	become	permanent.	The	identification	and	treatment	of	
the underlying disease is of crucial importance.
Erythromelalgia is a rare condition that occurs, in the ma-
jority of cases, in association with myeloproliferative diseases 
(59%	 in	 polycythemia	 vera,	 38%	 in	 essential	 thrombocyto-
sis).23 The diagnostic criteria comprise burning pain accom-
panied by increased cutaneous temperature and skin ery-
thema of the lower extremities; precipitation of symptoms by 
heat, standing and exercising; relief of symptoms by cooling 
or elevation of the extremity.
It can be divided into early and adult-onset, according to 
the	age	of	the	patient,	being	the	adult	form	further	classified	
into primary or secondary. Early-onset erythromelalgia occurs 
in children, with a mean age of 10 years old and a female 
prevalence. It has a bilateral and symmetrical distribution 
and it commonly affects the ankles, feet and distal portion 
of lower legs. Adult-onset erythromelalgia can be idiopathic 
or primary if it is not associated with any other disease, ha-
ving a male prevalence and a mean age of onset between 30 
and 80 years old. There is also bilateral involvement of extre-
mities and symptoms can be relieved by the use of aspirin. 
Secondary erythromelalgia is commonly associated with a 
myeloproliferative	disorder	(polycythemia	vera,	myelofibrosis,	
chronic	myelogenous	 leukemia)	and	in	85%	of	patients;	 the	
cutaneous symptoms develop before the myeloproliferative 
disorder (average time of 2 and a half years). It has also been 
reported to occur in association with systemic lupus erythe-
matosus, rheumatoid arthritis, pregnancy, diabetes mellitus, 
vasculitis and ingestion of certain drugs. It is thought to be 
caused by platelet hyperaggregability and activation that 
then leads to blockage of the arterioles.23
Vasculitis	is	a	condition	in	which	there	is	inflammation	and	
fibrinoid	necrosis	of	the	blood	vessel	wall.	There	are	several	
proposed	classification	systems,	some	focused	on	the	vessel	
diameter	and	others	based	on	histologic	findings.	It	can	also	
be further divided into primary or idiopathic and secondary 
(infections,	chronic	inflammation	or	neoplasms).
The	 systemic	 vasculitis	 can	 be	 classified	 according	 to	
the size of the vessels involved into small-vessel vasculitis 
(Wegener’s granulomatosis, Churg-Strauss syndrome, mi-
croscopic polyarteritis, Henoch-Schonlein purpura, essential 
cryoglobulinemic vasculitis and cutaneous leukocytoclastic 
vasculitis), medium-sized vessel vasculitis (polyarteritis nodo-
sa and Kawasaki disease) and large-vessel vasculitits (giant 
cell or temporal arteritis and Takayasu arteritis). All of them 
can have systemic symptoms, which include neurologic, re-
nal, gastrointestinal, arthralgias and fever. The clinical and 
physiopathological	features	of	each	of	them	are	very	specific	
and extensive and beyond the purpose of this article.
The autoimmune etiology can be explained by three main 
mechanisms: immune complex deposition in vessel walls or 
in situ formation; direct autoantibody binding to antigens ex-
pressed in vessel walls and leukocyte activation by antibo-
dies	with	 specificity	 to	 certain	 antigens	 expressed	 in	 these	
cells (antineutrophil cytoplasmic autoantibodies).24 The most 
common vasculitis associated with malignancy are cutaneous 
leukocytoclastic vasculitis and polyarteritis nodosa, occuring 
in	up	to	5%	of	the	patients.2
It has been postulated that tumoral cells can produce spe-
cific	antigens	that	can	interact	with	self-antigens	and	lead	to	
the development of paraneoplastic vasculitis. The diagnostic 
criteria of paraneoplastic vasculitis proposed by McLeanet et 
al25 are the simultaneous appearance of both vasculitis and 
neoplasms and their parallel clinical course. Most of these 
occur in association with hematological malignancies, mostly 
lymphoproliferative diseases, hairy cell leukemia, Hodgkin’s 
disease, chronic myelogenous leukemia, myelodysplastic 
syndromes and multiple myeloma.2 Leukocytoclastic vascu-
litis	is	the	most	common	one	(30	to	40%	of	all	paraneoplastic	
vasculitides). The direct or indirect action of malignant cells 
as sensitizing agents that release cytokines and damage the 
vascular endothelium is one of the proposed pathological me-
chanisms; however, further investigation needs to be done.25
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MANIFESTAÇÕES CUTÂNEAS PARANEOPLÁSICAS
The signs and symptoms of paraneoplastic vasculitis are 
similar to those in patients without an underlying malignancy 
and	include	unspecific	cutaneous	lesions	(palpable	purpura	
on the lower extremities, livedo reticularis, ulcers and digital 
finger	necrosis),	peripheral	neuropathy,	anasarca	(secondary	
to nephrotic syndrome), asymmetric polyarthritis and fever.
The differential diagnosis includes recovery phase of fros-
tbite, complex regional pain syndrome, autonomic dysfunc-
tion, hyper perfusion phase of Raynaud syndrome, peripheral 
vascular disease and cellulitis.23
The treatment of secondary erythromelalgia consists of a 
daily dose of 500 mg of acetylsalicylic acid. In the presence 
of vasculitis, corticosteroids alone or in association with imun-
nossupressive agents are the drugs of choice.
Other Skin Disorders
These are cutaneous syndromes characterized by the pre-
sence of small patches, papules or large plaques with a rai-
sed border. Most of them are associated with solid tumors 
but acanthosis nigricans, sign of Leser-Trélat and acquired 
ichthyosis can be observed in hematological neoplasms.26-28
Acanthosis nigricans	is	defined	by	the	rapid	onset	of	hyper	
pigmented	 velvety	 changes	 of	 the	 flexural	 surfaces	 (neck,	 
armpits, groin). It may also involve extensor surfaces (elbows, 
knees, knuckles) and, when it is associated with malignancy, 
the lips (in the form of glossitis), oral mucosa and palms are 
also involved.11 In approximately one third of cases of malig-
nant acanthosis nigricans, patients present with skin changes 
before any signs of cancer. In another one third of cases, the 
lesions of acanthosis nigricans arise simultaneously with the 
neoplasm and in the remaining one third of cases, the skin 
findings	 manifest	 sometime	 after	 the	 diagnosis	 of	 cancer.	
Malignant acanthosis nigricans has been reported to appear 
abruptly and exuberantly and may be associated with a higher 
rate of pruritus.26
The	sign	of	Leser-Trélat	has	been	defined	as	 the	sudden	
appearance and rapid increase in size and number of se-
borrheic keratoses in association with the development of an 
internal malignancy.27 Initially assumed as an incomplete va-
riant of acanthosis nigricans (already established as a marker 
of internal malignancy), it is nowadays thought to be due to a 
genetic abnormality which is only expressed in the presence 
of a malignant carcinoma. Additionally, the decreased host 
immunity and dysregulation on epidermal cell turnover are 
thought to contribute to the development of the cancer and 
of the seborrheic keratoses.27 The cutaneous lesions them-
selves	are	benign	and	do	not	require	any	specific	treatment.
Acquired ichthyosis (AI) is a condition characterized by dry, 
rough	skin	with	prominent	scaling,	resembling	fish	scale.	AI	
most commonly occurs in adulthood and manifests as sym-
metric scaling, with a coloration that can range from white to 
brown and primarily affecting trunk and extensor surfaces of 
the	limbs.	It	occurs	when	there	is	a	disruption	in	cornification,	
leading to hyperkeratosis, scaling and abnormalities on the 
barrier function of stratum corneum.28 AI has been described 
in association with Hodgkin and non-Hodgkin lymphomas, 
multiple myeloma, HIV infection, malnutrition and autoimmu-
ne disorders.28 The most commonly associated malignancy 
is	Hodgkin’s	disease,	occurring	in	70%	to	80%	of	the	cases.2 
Once the diagnosis is established, the main purpose is the 
identification	of	the	underlying	disease.	General	treatment	in-
cludes hydration, and keratolytics (salicylic acid, urea, lactic 
acid) and additional care is needed to prevent skin infections, 
as the barrier function is impaired.
Discussion
Cutaneous paraneoplastic syndromes may occur before, af-
ter or concomitantly with the cancer diagnosis. Their clinical 
features do not usually differ from the patients without a ma-
lignancy, being the patient history and careful clinical exami-
nation of essential importance.
The most commonly associated hematological malignan-
cies are, in lymphoproliferative diseases, Hodgkin and non-
-Hodgkin lymphoma, chronic lymphocytic leukemia, multiple 
myeloma and Waldenstrom macroglobulinemia; in myelopro-
liferative disorders, acute myelogenous leukemia, myelodys-
plasic	syndromes	and	primary	myelofibrosis.
These syndromes usually show a favorable response to 
systemic corticosteroids but successful resolution typically 
occurs only after eradication of the underlying malignancy, 
exception being made to paraneoplastic pemphigus (which 
is refractory to therapy and usually shows an independent 
course from the malignancy). Overall, their presence is an 
indicator of a poor prognosis.17			■
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